Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib and Waldenstrom's macroglobulinemia.
Pascal L, Gay J, Willekens C, Wemeau M, Balkaran S, Robu D, Roccaro A, Morel P, Ghobrial I, Leleu X. Pascal L, et al. Among authors: willekens c. Expert Opin Pharmacother. 2009 Apr;10(5):909-16. doi: 10.1517/14656560902800160. Expert Opin Pharmacother. 2009. PMID: 19351237 Review.
Prognostic value of PINI index in patients with multiple myeloma.
Dupire S, Wemeau M, Debarri H, Pascal L, Hivert B, Willekens C, Boyle E, Manier S, Béatrice T, Onraed B, Faucompré JL, Hennache B, Dumontet C, Facon T, Leleu X. Dupire S, et al. Among authors: willekens c. Eur J Haematol. 2012 Apr;88(4):306-13. doi: 10.1111/j.1600-0609.2011.01740.x. Epub 2012 Jan 4. Eur J Haematol. 2012. PMID: 22126676
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.
Kayser S, Schlenk RF, Lebon D, Carre M, Götze KS, Stölzel F, Berceanu A, Schäfer-Eckart K, Peterlin P, Hicheri Y, Rahme R, Raffoux E, Chermat F, Krause SW, Aulitzky WE, Rigaudeau S, Noppeney R, Berthon C, Görner M, Jost E, Carassou P, Keller U, Orvain C, Braun T, Saillard C, Arar A, Kunzmann V, Wemeau M, De Wit M, Niemann D, Bonmati C, Schwänen C, Abraham J, Aljijakli A, Haiat S, Krämer A, Reichle A, Gnadler M, Willekens C, Spiekermann K, Hiddemann W, Müller-Tidow C, Thiede C, Röllig C, Serve H, Bornhäuser M, Baldus CD, Lengfelder E, Fenaux P, Platzbecker U, Adès L. Kayser S, et al. Among authors: willekens c. Haematologica. 2021 Dec 1;106(12):3100-3106. doi: 10.3324/haematol.2021.278722. Haematologica. 2021. PMID: 34047178 Free PMC article.
Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.
Willekens C, Rahme R, Duchmann M, Vidal V, Saada V, Broutin S, Delahousse J, Renneville A, Marceau A, Clappier E, Uzunov M, Rossignol J, Pascal L, Simon L, Micol JB, Pasquier F, Raffoux E, Preudhomme C, Quivoron C, Itzykson R, Penard-Lacronique V, Paci A, Fenaux P, Attar EC, Frattini M, Braun T, Ades L, De Botton S. Willekens C, et al. Leuk Lymphoma. 2021 Feb;62(2):438-445. doi: 10.1080/10428194.2020.1832661. Epub 2020 Oct 12. Leuk Lymphoma. 2021. PMID: 33043739
Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).
Quinquenel A, Willekens C, Dupuis J, Royer B, Ysebaert L, De Guibert S, Michallet AS, Feugier P, Guieze R, Levy V, Delmer A. Quinquenel A, et al. Among authors: willekens c. Am J Hematol. 2015 Mar;90(3):204-7. doi: 10.1002/ajh.23909. Epub 2015 Jan 16. Am J Hematol. 2015. PMID: 25428829 Free article.
Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy.
Abdayem P, Ibrahim N, El Dakdouki Y, Willekens C, Ghez D, A Rouche J, Dartigues P, Desmaris R, Danu A, Rossignol J, Lazarovici J, Fermé C, Ribrag V, Michot JM. Abdayem P, et al. Among authors: willekens c. Eur J Haematol. 2021 Apr;106(4):574-583. doi: 10.1111/ejh.13589. Epub 2021 Feb 4. Eur J Haematol. 2021. PMID: 33512026
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S, Cherait A, Berthon C, Willekens C, Park S, Rigal M, Brechignac S, Thépot S, Quesnel B, Gardin C, Adès L, Fenaux P, Braun T. Harel S, et al. Among authors: willekens c. Leuk Res. 2015 May;39(5):501-4. doi: 10.1016/j.leukres.2015.02.004. Epub 2015 Feb 16. Leuk Res. 2015. PMID: 25735917
60 results